NeurAxis, Inc.
NRXSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Craig-Hallum | maintain | Buy | Mar 20, 2026 |
| Craig-Hallum | maintain | Buy | Dec 22, 2025 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.19 | $-0.32 | $1.9M | $2.0M |
| May 12, 2026 | $-0.18 | $-0.19 | $1.6M | $1.4M |
| Mar 19, 2026 | $-0.17 | $-0.21 | $968.0K | $850.0K |
| Nov 10, 2025 | $-0.24 | $-0.20 | $811.4K | $1.0M |
| Aug 12, 2025 | $-0.22 | $-0.19 | $894.0K | $983.6K |
| May 12, 2025 | $-0.31 | $-0.24 | $895.7K | $725.0K |
| Mar 20, 2025 | $-0.21 | $0.04 | $761.1K | $3.6M |
| Nov 12, 2024 | $-0.25 | $1.54 | $666.6K | $3.1M |
News
CARMEL, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its third quarter period ended September 30, 2026, on Monday, November 9, 2026, before market open.
Total national coverage footprint for PENFS increases to over 147 million covered lives Total national coverage footprint for PENFS increases to over 147 million covered lives
NeurAxis (NASDAQ: NRXS - Get Free Report) and NovoCure (NASDAQ: NVCR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. Insider and Institutional Ownership 11.8% of NeurAxis shares are
NeurAxis (NASDAQ: NRXS - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Institutional and Insider Ownership 11.8% of NeurAxis shares are held
CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer.
MariMed (OTCMKTS:MRMD - Get Free Report) and NeurAxis (NASDAQ: NRXS - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations. Analyst Ratings This is a breakdown of recent ratings
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”).
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.
NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.
NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
KODK and NRXS are worth watching for their growth.
NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.
NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript